간질환 진단 시장 예측(-2034년) - 질환 유형별, 진단 방법, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Liver Disease Diagnostics Market is accounted for $50.9 billion in 2026 and is expected to reach $95.0 billion by 2034 growing at a CAGR of 8.1% during the forecast period. Diagnostics for liver diseases are essential for determining and treating a wide range of liver-related conditions. These diagnostics include a variety of procedures and imaging methods designed to evaluate the liver's health, identify anomalies, and identify the underlying causes of liver diseases. Moreover, blood tests to measure liver enzyme levels, such as alanine transaminase (ALT) and aspartate transaminase (AST), as well as tests to assess the presence of particular antibodies or viral markers, are commonly used diagnostic tools.

According to report of World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year.

Market Dynamics:

Driver:

Growing consciousness and screening initiatives

Liver disease diagnostics are in high demand due to growing public awareness of the seriousness of liver diseases, which has been fueled by campaigns from non-profits and healthcare groups. Additionally, early-stage diagnoses are increasing as a result of proactive screening programs, which typically target high-risk populations such as those with a history of substance abuse or particular demographics predisposed to liver disorders. In addition to lessening the strain on healthcare systems, this increased focus and awareness of preventive healthcare also give people the power to take control of their liver health through routine screenings.

Restraint:

Exorbitant expense of advanced diagnosis

A major barrier is the expense of cutting-edge liver disease diagnostics, which include sophisticated imaging methods and molecular testing. The total cost is influenced by a high initial investment, ongoing maintenance expenses, and the requirement for specialized training. Furthermore, this financial obstacle prevents these diagnostics from being widely used and made accessible to patients and healthcare organizations alike.

Opportunity:

Developments in customized medicine

There is a large opportunity for the liver disease diagnostics market due to the changing face of personalized medicine. Liver disease diagnosis and treatment can be made more accurate by customizing diagnostic strategies based on a person's genetic composition, lifestyle choices, and unique disease features. Moreover, the creation of targeted diagnostic tools is made possible by developments in genomics and molecular profiling, which open the door to more efficient and customized patient care.

Threat:

Issues with compliance and regulatory difficulties

The market for liver disease diagnostics is threatened by stricter and more dynamic regulatory environments. Companies face difficulties in terms of time, resources, and possible delays in product launches when they must follow compliance requirements, secure required approvals, and navigate complex regulatory processes. However, for market participants, non-compliance poses a serious risk of legal problems, market withdrawals, or restrictions.

Covid-19 Impact:

The market for liver disease diagnostics has been significantly impacted by the COVID-19 pandemic. The pandemic's worldwide disruption, which included lockdowns, overburdened healthcare systems, and the redirection of resources to fight the virus, temporarily, reduced the number of elective surgeries and routine medical visits, which had an impact on the demand for diagnostic services as a whole. Additionally, market participants faced difficulties due to delays in R&D projects, interruptions in the supply chain, and changes in healthcare priorities. Positively, the pandemic accelerated the adoption of tele-health and remote monitoring solutions by highlighting the significance of strong diagnostic capabilities.

The Non-alcoholic Fatty Liver Disease (NAFLD) segment is expected to be the largest during the forecast period

The non-alcoholic fatty liver disease (NAFLD) segment is anticipated to hold the largest share. Since obesity and metabolic syndrome are becoming more common, non-alcoholic fatty liver disease (NAFLD) has emerged as a major global cause of chronic liver disease. Furthermore, the rising prevalence of NAFLD, which can vary from mild hepatic steatosis to more serious illnesses like non-alcoholic steatohepatitis (NASH), is what drives the segment's dominance. Because of this, there has been a noticeable increase in the need for liver disease diagnostics, such as cutting-edge imaging methods and blood tests for precise NAFLD diagnosis and staging.

The Research Institutes segment is expected to have the highest CAGR during the forecast period

The segment with the highest CAGR during the estimation period is research institutes. Research institutes are essential for fostering innovation and technical progress in the development of diagnostic instruments and procedures. The robust growth of this segment can be attributed to the growing emphasis on translational research, biomarker discovery, and the development of innovative diagnostic technologies. Moreover, research institutes conduct clinical studies, validate diagnostic assays, and lead the way in developing novel diagnostic techniques in partnership with diagnostic companies and healthcare providers. Government grants and funding, along with the increased volume of research activity, are driving the Research Institutes sector forward.

Region with largest share:

North America is expected to hold the largest market share. A strong regulatory environment that encourages innovation, high healthcare spending, technological advancements, and a well-established healthcare infrastructure are some of the reasons for the region's dominance. Additionally, North America holds a dominant position in the liver disease diagnostics market due in part to the existence of important market players, research institutions, and a proactive approach towards adopting advanced diagnostic technologies.

Region with highest CAGR:

The healthcare diagnostics market is expected to grow at the highest CAGR in the Asia-Pacific region. The region's expanding population, the rising frequency of chronic diseases, the increased public awareness of early disease detection, and the significant investments made in healthcare infrastructure are all contributing factors to this. The rapid growth is mostly being driven by middle-class population expansion, government initiatives to increase healthcare accessibility, and technological advancements in countries like China and India. Furthermore, the Asia-Pacific region is well-positioned for strong growth in the healthcare diagnostics industry due to its dynamic nature and emphasis on implementing cutting-edge diagnostic solutions.

Key players in the market

Some of the key players in Liver Disease Diagnostics market include Abbott Laboratories, Horiba Medical, F. Hoffmann-La Roche Ltd., Cosara Diagnostics Pvt Ltd, Laboratory Corporation of America Holdings, Bio-Rad Laboratories Inc., Meril Life Sciences Pvt. Ltd., Fujifilm Corporation, PerkinElmer, Biosino Bio-Technology and Science Inc, Quest Diagnostics Incorporated, Trivitron Healthcare, Boston Scientific Corporation, Qiagen N.V, Siemens Healthcare GmbH, Thermo Fisher Scientific Inc and Randox Laboratories Ltd.

Key Developments:

In December 2023, F. Hoffmann-La Roche Ltd. announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. ("Carmot"), a privately owned US company based in Berkeley, California. Carmot's R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

In August 2022, HORIBA, one of the global leaders in a wide range of medical diagnostic equipment, and SigTuple, a medtech company that develops AI-powered digital microscopy solutions, announced today a partnership to accelerate adoption of SigTuple's AI100 across the Indian subcontinent. HORIBA, a medical diagnostic company, and SigTuple, a MedTech company, on Monday, announced a partnership to accelerate the adoption of SigTuple's AI100 across the Indian subcontinent.

Disease Types Covered:

• Viral Hepatitis
• Alcoholic Liver Disease
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Liver Cancer
• Other Disease Types

Techniques Covered:

• Endoscopy
• Biopsy
• Imaging Techniques
• Laboratory Tests
• Other Techniques

End Users Covered:

• Hospitals
• Laboratories
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Liver Disease Diagnostics Market, By Disease Type

• 5.1 Introduction
• 5.2 Viral Hepatitis
• 5.3 Alcoholic Liver Disease
• 5.4 Non-alcoholic Fatty Liver Disease (NAFLD)
• 5.5 Liver Cancer
• 5.6 Other Disease Types

6 Global Liver Disease Diagnostics Market, By Technique

• 6.1 Introduction
• 6.2 Endoscopy
• 6.3 Biopsy
• 6.4 Imaging Techniques
  • 6.4.1 Ultrasound
  • 6.4.2 MRI
  • 6.4.3 CT Scan
• 6.5 Laboratory Tests
  • 6.5.1 Blood Tests
  • 6.5.2 Liver Function Tests
  • 6.5.3 Genetic Tests
• 6.6 Other Techniques

7 Global Liver Disease Diagnostics Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Laboratories
• 7.4 Research Institutes
• 7.5 Other End Users

8 Global Liver Disease Diagnostics Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Abbott Laboratories
• 10.2 Horiba Medical
• 10.3 F. Hoffmann-La Roche Ltd.
• 10.4 Cosara Diagnostics Pvt Ltd
• 10.5 Laboratory Corporation of America Holdings
• 10.6 Bio-Rad Laboratories Inc.
• 10.7 Meril Life Sciences Pvt. Ltd.
• 10.8 Fujifilm Corporation
• 10.9 PerkinElmer
• 10.10 Biosino Bio-Technology and Science Inc
• 10.11 Quest Diagnostics Incorporated
• 10.12 Trivitron Healthcare
• 10.13 Boston Scientific Corporation
• 10.14 Qiagen N.V
• 10.15 Siemens Healthcare GmbH
• 10.16 Thermo Fisher Scientific Inc
• 10.17 Randox Laboratories Ltd.